French implementation of new European pharma patent regime now a reality

19 March 2007

French implementation of the revised European Union pharmaceuticals regime has finally become law. Directive 2004/27 (amending Directive 2001/83/EC) on the Community code relating to medicinal products for human use should have been implemented into national laws by October 30, 2005, observe partners at the UK patent law specialist Linklaters. A delay of over a year in France has finally ended, with the introduction of Law No 2007-248 dated February 26, 2007.

The "Bolar" exemption

The amendment has created a new exception to the rights of patentees. Article L 613-5 of the Intellectual Property Code has been changed to provide that: "the rights afforded by the patent shall not extend to (

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight